Phaseline

Targets › PDE10A

PDE10A (cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Psychiatry.

Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate. (UniProt, Q9Y233)

Open in Phaseline: the race on PDE10A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Noema PharmaGemlapodect (NOE-105)
selective PDE10A inhibitor
PDE10APhase 2Tourette Syndrome–

Conditions

Tourette Syndrome (1)

Modalities

small molecule (1)

Companies

Noema Pharma (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.